Cancer

Cover image for Vol. 121 Issue 15

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.068

ISI Journal Citation Reports © Ranking: 2014: 32/211 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 147
  1. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      A diagnostic model for impending death in cancer patients: Preliminary report

      David Hui, Kenneth Hess, Renata dos Santos, Gary Chisholm and Eduardo Bruera

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29602

      In this prospective, observational study of hospitalized cancer patients, a diagnostic recursive partitioning model, based on bedside physical signs, has been developed for impending death within 3 days. This model is accurate, is applicable both at admission and during hospitalization, and may help clinicians to formulate the diagnosis of impending death.

    2. Clinical Trials
      Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia

      Nicholas J. Short, Michael J. Keating, William G. Wierda, Stefan Faderl, Alessandra Ferrajoli, Zeev Estrov, Susan C. Smith and Susan M. O'Brien

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29605

      The addition of multiple doses of rituximab to fludarabine, cyclophosphamide, and rituximab does not significantly improve response rates or long-term outcomes for patients with previously untreated chronic lymphocytic leukemia. This regimen is associated with an increased incidence of therapy-related myelodysplastic syndrome/therapy-related acute myelogenous leukemia.

  2. Correspondence

    1. Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer: The question is still open

      Soodabeh ShahidSales, Majid Ghayour Mobarhan, Faezeh Ghasemi, Sharareh Gholamin and Amir Avan

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29598

  3. Original Articles

    1. Disease Site

      Melanoma
      Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

      Alexander M. Menzies, James S. Wilmott, Martin Drummond, Serigne Lo, Megan Lyle, Matthew M. K. Chan, John F. Thompson, Alex Guminski, Matteo S. Carlino, Richard A. Scolyer, Richard F. Kefford and Georgina V. Long

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29586

      This study demonstrates that long-term survival occurs for patients with mitogen-activated protein kinase inhibitor treatment alone, and sex, serum lactate dehydrogenase, BRAF genotype, and primary melanoma ulceration status are independent factors associated with treatment outcomes. Patients with a complete response to treatment have the best survival, but relapses still occur.

    2. Gastrointestinal Disease
      Molecular markers and pathway analysis of colorectal carcinoma in the Middle East

      Shaham Beg, Abdul K. Siraj, Sarita Prabhakaran, Rong Bu, Maha Al-Rasheed, Mehar Sultana, Zeeshan Qadri, Mohammed Al-Assiri, Rami Sairafi, Fouad Al-Dayel, Nasser Al-Sanea, Shahab Uddin and Khawla S. Al-Kuraya

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29580

      The results of the current study indicate the need to unravel the molecular genetic basis of colorectal carcinoma to further subcategorize colorectal carcinoma cases. They also emphasize the need to perform further studies on different populations to develop a better understanding of the exact role and incidence of genetic pathways.

    3. Discipline

      Outcomes Research
      Impact of care at comprehensive cancer centers on outcome: Results from a population-based study

      Julie A. Wolfson, Can-Lan Sun, Laura P. Wyatt, Arti Hurria and Smita Bhatia

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29576

      Among patients aged 22 to 65 years in Los Angeles County with newly diagnosed adult-onset cancer, those treated at National Cancer Institute-designated comprehensive cancer centers experienced superior survival when compared with those treated at community facilities. Barriers to care at these facilities included race/ethnicity, insurance, socioeconomic status, and distance to the facility.

    4. Pediatric Oncology
      Symptom profiles in children with advanced cancer: Patient, family caregiver, and oncologist ratings

      Donna S. Zhukovsky, Cathy L. Rozmus, Rhonda S. Robert, Eduardo Bruera, Robert J. Wells, Gary B. Chisholm, Julio A. Allo and Marlene Z. Cohen

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29597

      To the authors' knowledge, the current study is among the first to systematically document symptom prevalence as reported by children, family caregivers, and oncologists in a pediatric outpatient oncology setting using a validated tool specifically designed for that purpose. Proxy and patient reports are often not congruent, emphasizing the importance of understanding the meaning behind symptom reports for the provision of optimal care.

    5. Outcomes Research
      Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

      Musa Yilmaz, Amit Lahoti, Susan O'Brien, Graciela M. Nogueras-González, Jan Burger, Alessandra Ferrajoli, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Elias Jabbour, Hagop Kantarjian and Jorge E. Cortes

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29587

      The administration of tyrosine kinase inhibitors may be safe in the setting of chronic kidney disease in patients with chronic myeloid leukemia.

  4. Commentary

    1. You have full text access to this OnlineOpen article
      Reflections from a chair: Leadership of a clinical department at an academic medical center

      Christopher G. Willett

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29588

      The major goals of a Chair of a Clinical Department at an Academic Medical Center are advancing the care of patients as well as the educational and research missions of the Department. True excellence of a Department is achieved by the innovation of its Faculty.

  5. Original Articles

    1. Discipline

      Disparities Research
      Fertility preservation knowledge, counseling, and actions among adolescent and young adult patients with cancer: A population-based study

      Margarett Shnorhavorian, Linda C. Harlan, Ashley Wilder Smith, Theresa H.M. Keegan, Charles F. Lynch, Pinki K. Prasad, Rosemary D. Cress, Xiao-Cheng Wu, Ann S. Hamilton, Helen M. Parsons, Gretchen Keel, Sarah E. Charlesworth, Stephen M. Schwartz and AYA HOPE Study Collaborative Group

      Article first published online: 27 JUL 2015 | DOI: 10.1002/cncr.29328

      Among the most important challenges faced by adolescent and young adult cancer survivors is the toxic effect of cancer therapy on future fertility. This study addresses key gaps in knowledge regarding whether characteristics of adolescent and young adult patients with cancer or their health care providers are associated with fertility counseling or making arrangements for fertility preservation.

    2. Epidemiology
      Opioids and breast cancer recurrence: A Danish population-based cohort study

      Deirdre P. Cronin-Fenton, Uffe Heide-Jørgensen, Thomas P. Ahern, Timothy L. Lash, Peer M. Christiansen, Bent Ejlertsen, Per Sjøgren, Henrik Kehlet and Henrik T. Sørensen

      Article first published online: 24 JUL 2015 | DOI: 10.1002/cncr.29532

      The association between opioid prescriptions and breast cancer recurrence is investigated. The findings indicate no evidence of an effect of opioids on breast cancer recurrence in a cohort of 34,188 patients with early stage breast cancer in Denmark.

    3. Medical Oncology
      Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

      Jennifer E. Vaughn, Mohamed L. Sorror, Barry E. Storer, Thomas R. Chauncey, Michael A. Pulsipher, Richard T. Maziarz, Michael B. Maris, Parameswaran Hari, Ginna G. Laport, Georg N. Franke, Edward D. Agura, Amelia A. Langston, Andrew R. Rezvani, Rainer Storb, Brenda M. Sandmaier and David G. Maloney

      Article first published online: 24 JUL 2015 | DOI: 10.1002/cncr.29498

      Nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) can provide a long-term cure for patients with previously treated mantle cell lymphoma. Patients with mantle cell lymphoma in pre-HCT remission and patients with relapsed/refractory disease have comparable survival after nonmyeloablative allogeneic HCT.

    4. Disease Site

      Head and Neck Disease
      Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma

      Guoqing Qian, Ning Jiang, Dongsheng Wang, Scott Newman, Sungjin Kim, Zhengjia Chen, Gabriela Garcia, Gavin MacBeath, Dong M. Shin, Fadlo R. Khuri, Zhuo G. Chen and Nabil F. Saba

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29549

      A high heregulin messenger RNA (mRNA) level correlates with poor overall survival in patients with oropharyngeal squamous cell carcinoma, regardless of p16 status. In the current study, heregulin mRNA expression appears to be higher in patients with head and neck squamous cell carcinoma compared with 5 other solid tumors examined, including adenocarcinoma of the breast, ovary, and lung, and squamous cell carcinoma of the lung and cervix.

    5. Discipline

      Supportive Care
      You have full text access to this OnlineOpen article
      Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial

      Anna M. Sawka, Sharon Straus, Gary Rodin, Lineke Heus, James D. Brierley, Richard W. Tsang, Lorne Rotstein, Shereen Ezzat, Phillip Segal, Amiram Gafni, Kevin E. Thorpe and David P. Goldstein

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29548

      In this extended follow-up study of a randomized controlled trial of a thyroid cancer treatment patient decision aid, patient decision aid users perceive themselves to be significantly more informed about the choice of radioactive iodine treatment, although their decision satisfaction and regret are not significantly different from those of controls not exposed to the patient decision aid. Patient decision aid utilization has no significant negative impact on cancer-related worry, mood, or trust in the treating physician in long-term follow-up.

    6. Epidemiology
      Overall and central adiposity and breast cancer risk in the sister study

      Alexandra J. White, Hazel B. Nichols, Patrick T. Bradshaw and Dale P. Sandler

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29552

      The results of the current prospective study with examiner-measured body size indicate that waist circumference is independently and positively associated with both premenopausal and postmenopausal breast cancer risk after accounting for overall adiposity. This finding is potentially important for future breast cancer trends as average waist circumferences continue to increase in the United States.

    7. Disease Site

      Hematologic Malignancies
      Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

      Philip A. Thompson, Susan M. O'Brien, William G. Wierda, Alessandra Ferrajoli, Francesco Stingo, Susan C. Smith, Jan A. Burger, Zeev Estrov, Nitin Jain, Hagop M. Kantarjian and Michael J. Keating

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29566

      A complex metaphase karyotype, determined by conventional cytogenetic analysis, is associated with very high-risk disease in patients with relapsed and/or refractory chronic lymphocytic leukemia treated with ibrutinib-based regimens. Patients with del(17p) who do not have a complex karyotype may have a relatively favorable outcome.

    8. Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study

      Koichi Ogura, Tomohiro Fujiwara, Hideo Yasunaga, Hiroki Matsui, Dae-Geun Jeon, Wan Hyeong Cho, Hiroaki Hiraga, Takeshi Ishii, Tsukasa Yonemoto, Hiroto Kamoda, Toshifumi Ozaki, Eiji Kozawa, Yoshihiro Nishida, Hideo Morioka, Toru Hiruma, Shigeki Kakunaga, Takafumi Ueda, Yusuke Tsuda, Hirotaka Kawano and Akira Kawai

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29575

      Prognostic nomograms for osteosarcoma have been developed and externally validated through multi-institutional collaboration. These prognostic nomograms are the first to be developed and externally validated for osteosarcoma.

  6. Review Articles

    1. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy

      Sarah K. Tasian, Mignon L. Loh and Stephen P. Hunger

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29573

      Advances in the genomic characterization of childhood acute lymphoblastic leukemia have led to modern risk-stratification and chemotherapeutic modifications for specific subsets of patients. The incorporation of molecularly targeted agents into therapy has significantly improved or has the potential to improve outcomes for patients with high-risk acute lymphoblastic leukemia.

  7. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

      Jordi Ribera, Mireia Morgades, Lurdes Zamora, Pau Montesinos, Inés Gómez-Seguí, Marta Pratcorona, Josep Sarrà, Ramon Guàrdia, Josep Nomdedeu, Mar Tormo, Joaquin Martínez-Lopez, Jesús-María Hernández-Rivas, José González-Campos, Pere Barba, Lourdes Escoda, Eulàlia Genescà, Francesc Solé, Fuensanta Millá, Evarist Feliu, Josep-Maria Ribera and for the Spanish PETHEMA Group and the Spanish Society of Hematology

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29579

      Deletions of early B-cell factor 1, cyclin-dependent kinase inhibitor 2A/B, and Ikaros family zinc finger 1 are independent markers of a poor prognosis for uniformly treated adolescent and adult patients with B precursor acute lymphoblastic leukemia.

    2. Discipline

      Symptom Control and Palliative Care
      Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial

      Lara Traeger, Theresa M. McDonnell, Caitlin E. McCarty, Joseph A. Greer, Areej El-Jawahri and Jennifer S. Temel

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29585

      A proactive, telephone-based nursing intervention delivered by a patient's oncology nurse practitioner does not appear to improve patient-reported symptom burden in adults initiating chemotherapy for nonmetastatic cancer. Critical factors underlying null results will inform future symptom management trials.

    3. Clinical Trials
      Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications

      Dana E. Rathkopf, Steven M. Larson, Aseem Anand, Michael J. Morris, Susan F. Slovin, David R. Shaffer, Glenn Heller, Brett Carver, Neal Rosen and Howard I. Scher

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29578

      The combination of gefitinib and everolimus does not result in significant antitumor activity in castration-resistant prostate cancer. For some patients, there is evidence of relief of the phosphoinositide 3-kinase feedback inhibition associated with increased androgen receptor activity.

    4. You have full text access to this OnlineOpen article
      A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

      Johanna C. Bendell, Robin K. Kelley, Kent C. Shih, Jennifer A. Grabowsky, Emily Bergsland, Suzanne Jones, Thomas Martin, Jeffrey R. Infante, Paul S. Mischel, Tomoo Matsutani, Shuichan Xu, Lilly Wong, Yong Liu, Xiaoling Wu, Deborah S. Mortensen, Rajesh Chopra, Kristen Hege and Pamela N. Munster

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29422

      CC-223 inhibits both mTORC1 and mTORC2, a feature thought to increase the efficiency of mTOR pathway suppression that distinguishes this agent from rapamycin and its analogs that primarily target mTORC1 alone. In a phase 1 study of patients with advanced solid tumors or multiple myeloma, CC-223 was tolerable with manageable toxicities, and treatment was associated with early signs of disease control, including tumor regression.

    5. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma

      William W. Tseng, Shouhao Zhou, Christina A. To, Peter F. Thall, Alexander J. Lazar, Raphael E. Pollock, Patrick P. Lin, Janice N. Cormier, Valerae O. Lewis, Barry W. Feig, Kelly K. Hunt, Matthew T. Ballo, Shreyaskumar Patel and Peter W. T. Pisters

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29544

      For patients with high-risk extremity and trunk soft tissue sarcoma, a novel, clinically relevant toxicity severity weight method is used to determine the maximum tolerated dose of neoadjuvant gemcitabine given with concurrent radiation therapy. Although toxicity assessment is the primary objective of this study, clinical outcomes are also encouraging.

  8. Editorials

  9. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

      W. Ray Kim, Rohit Loomba, Thomas Berg, Raul E. Aguilar Schall, Leland J. Yee, Phillip V. Dinh, John F. Flaherty, Eduardo B. Martins, Terry M. Therneau, Ira Jacobson, Scott Fung, Selim Gurel, Maria Buti and Patrick Marcellin

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29537

      Efficacy trials have shown that antiviral therapy improves the outcomes of patients with chronic hepatitis B virus infection. Based on the Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) risk calculator, long-term therapy with tenofovir disoproxil fumarate appears to be associated with a reduced incidence of hepatocellular carcinoma among patients without cirrhosis who meet treatment criteria.

    2. Discipline

      Symptom Control and Palliative Care
      Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial

      Charlotte Lund Rasmussen, Marc Klee Olsen, Anna Thit Johnsen, Morten Aagaard Petersen, Helena Lindholm, Line Andersen, Birgit Villadsen, Mogens Groenvold and Lise Pedersen

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29563

      The current double-blind, randomized, crossover trial investigates the effect of melatonin on fatigue, insomnia, loss of appetite, pain, and emotional function in patients with advanced cancer. Oral melatonin at a dose of 20 mg does not appear to improve fatigue or other symptoms in patients with advanced cancer.

    3. Disease Site

      Hepatobiliary Disease
      Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index

      Beomseok Suh, Jae Moon Yun, Sehhoon Park, Dong Wook Shin, Tae Hoon Lee, Hyung-Kook Yang, Eunmi Ahn, Hyejin Lee, Jin Ho Park and BeLong Cho

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29577

      FIB-4, an easily applicable liver fibrosis index, is highly predictive of the incidence of hepatocellular carcinoma among moderate to heavy alcoholics and is able to identify a subpopulation of alcoholics at particularly high risk for hepatocellular carcinoma. FIB-4 may be useful in hepatocellular carcinoma screening among alcoholics.

    4. Discipline

      Quality of Life
      Adoption and cancer survivors: Findings from a learning activity for oncology nurses

      Gwendolyn P. Quinn, Bradley J. Zebrack, Ivana Sehovic, Meghan L. Bowman and Susan T. Vadaparampil

      Article first published online: 14 JUL 2015 | DOI: 10.1002/cncr.29322

      Nurses are charged with following practice guidelines that include recommendations for appropriate reproductive health referrals. Cancer survivors would benefit from a health care provider who can provide education and concrete information when patients are making a decision regarding fertility and adoption.

    5. Disparities Research
      State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences

      Iris Lansdorp-Vogelaar, S. Lucas Goede, Jiemin Ma, Wu Xiau-Cheng, Karen Pawlish, Marjolein van Ballegooijen and Ahmedin Jemal

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29561

      A microsimulation modeling study demonstrates that disparities in colorectal cancer rates between Southern states and Northeastern states in the United States can be eliminated if Southern states attain screening uptake and colorectal cancer relative survival equal to those of Northeastern states.

  10. Editorial

    1. Comorbidity and the risk of venous thromboembolism in prostate cancer

      Shabbir M. H. Alibhai and Meagan E. O'Neill

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29536

      In this issue, Ording et al use the Danish Cancer Registry to examine the interaction between prostate cancer, comorbidity, and the risk of venous thromboembolism. Their findings suggest that severe comorbidity and prostate cancer interact to synergistically increase the risk of venous thromboembolism, although their small sample and other limitations demand caution in interpreting the findings. See also pages 000-000.

  11. Original Articles

    1. Discipline

      Epidemiology
      Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011

      Anne G. Ording, Erzsébet Horváth-Puhó, Timothy L. Lash, Vera Ehrenstein, Michael Borre, Mogens Vyberg and Henrik T. Sørensen

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29535

      The risk of venous thromboembolism is investigated in patients with prostate cancer and in a matched group of men without prostate cancer in Denmark. The results indicate that the risk of venous thromboembolism is greater for men with prostate cancer than for men in the general population, particularly among those who undergo surgery, those with high Gleason scores, and those in the D'Amico high-risk group.

    2. Symptom Control and Palliative Care
      Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer

      Virginia Sun, Marcia Grant, Marianna Koczywas, Bonnie Freeman, Finly Zachariah, Rebecca Fujinami, Catherine Del Ferraro, Gwen Uman and Betty Ferrell

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29567

      Family caregivers experience significant caregiver burden, psychological distress, and lower quality of life while caring for patients with lung cancer. An interdisciplinary palliative care intervention is effective in improving social well being, psychological distress, and caregiver burden across all disease stages.

  12. Review Articles

    1. You have full text access to this OnlineOpen article
      Applying precision medicine to the active surveillance of prostate cancer

      Chad A. Reichard, Andrew J. Stephenson and Eric A. Klein

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29496

      The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer. This review covers a wide range of possible applications of these tests to different clinical scenarios in the active surveillance of prostate cancer.

  13. Editorial

    1. Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma

      Christopher R. Flowers and Loretta J. Nastoupil

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29526

      Nodular lymphocyte-predominant Hodgkin lymphoma is an uncommon, indolent lymphoma with few prospective clinical studies with which to guide clinical management, thereby producing controversies and conflicting data regarding the optimal management of this entity. This lack of consensus complicates the understanding of whether racial differences in patient management represent variations that may portend a worse outcome.

  14. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base

      Adam J. Olszewski, Rajesh Shrestha and Nathaniel M. Cook

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29527

      Nodular lymphocyte-predominant Hodgkin lymphoma in black patients demonstrates distinct distributions of age, sex, and primary disease site, but survival is similar to that of white patients. In patients with early-stage nodular lymphocyte-predominant Hodgkin lymphoma, different treatment strategies are associated with similar overall survival.

    2. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma

      Patrick T. Griffin, Viet Q. Ho, William Fulp, Taiga Nishihori, Kenneth H. Shain, Melissa Alsina and Rachid C. Baz

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29533

      The salvage infusional chemotherapy regimens, including DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin), VTD-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide), and CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone), continue to play a role in the treatment of patients with recurrent/refractory multiple myeloma. In the current single-institution analysis, no differences in outcomes are observed among patients treated with the 3 salvage regimens, with the greatest benefit noted for those treated as a bridge to transplant.

    3. Discipline

      Clinical Trials
      Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis

      Robert C. G. Martin II, Charles R. Scoggins, Marshall Schreeder, William S. Rilling, Christopher J. Laing, Clifton M. Tatum, Lawrence R. Kelly, Ricardo D. Garcia-Monaco, Vivek R. Sharma, Todd S. Crocenzi and Steven M. Strasberg

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29534

      It is hypothesized that delivering irinotecan in drug-eluting beads via the hepatic artery will reduce systemic exposure and aim the agent at the location of liver metastases. mFOLFOX6 with bevacizumab and irinotecan drug-eluting beads via the hepatic artery is safe; it does not cause chemotherapy delivery delays or increase chemotherapy toxicity.

  15. Correspondence

    1. Reply to the long and winding road in cancer survivorship care

      Aaron J. Dawes and Melinda Maggard-Gibbons

      Article first published online: 2 JUL 2015 | DOI: 10.1002/cncr.29546

    2. The long and winding road in cancer survivorship care

      Ernesto Zanet, Mariagrazia Michieli and Umberto Tirelli

      Article first published online: 2 JUL 2015 | DOI: 10.1002/cncr.29545

  16. Editorial

    1. Does one size fit all? The updated ovarian cancer staging: Still a work in progress

      Linda R. Duska and Elise C. Kohn

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29521

      The International Federation of Gynecology and Obstetrics (FIGO) has recognized serous tubal intraepithelial carcinoma as a precursor lesion for high-grade serous epithelial ovarian cancer. Future staging systems should consider reclassifying stage based on tumor biologic behavior.

  17. Review Articles

    1. Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers

      Sarah M. Temkin and Nita L. Seibel

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29515

      Despite the risks of human papillomavirus–related disease, the uptake of human papillomavirus vaccination among childhood and adolescent cancer survivors has been low. The human papillomavirus vaccines are safe and effective, and increasing provider endorsements of vaccination in this population is important.

  18. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum

      Jaime Prat and for the FIGO Committee on Gynecologic Oncology

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29524

      The current article is an abridged version of the staging classification for cancer of the ovary, fallopian tube, and peritoneum, originally published in the International Journal of Gynecology and Obstetrics in January 2014.

    2. Discipline

      Disparities Research
      Racial differences in breast cancer survival in a large urban integrated health system

      Molly E. Roseland, Mary E. Pressler, Lois E. Lamerato, Rick Krajenta, Julie J. Ruterbusch, Jason C. Booza, Kendra Schwartz and Michael S. Simon

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29523

      Racial differences in breast cancer survival can be explained by clinical and socioeconomic factors. African American women with breast cancer remain disproportionately affected by unfavorable tumor characteristics and economic deprivation, which likely contribute to their increased overall mortality.

  19. Correspondence

    1. Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma

      Jessica N. Williams, Jean L. Koff and Christopher R. Flowers

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29508

      Reduced doses of R-CHOP, non-anthracycline-based regimens, and non-pegylated liposomal doxorubicin are potential alternative regimens for elderly patients with diffuse large B-cell lymphoma who cannot tolerate standard R-CHOP. Radiation therapy with abbreviated R-CHOP should also be further investigated as a treatment option in this population.

  20. Original Articles

    1. Discipline

      Clinical Trials
      A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

      Gunter von Minckwitz, Bettina Conrad, Toralf Reimer, Thomas Decker, Holger Eidtmann, Wolfgang Eiermann, John Hackmann, Volker Möbus, Frederik Marmé, Jochem Potenberg, Elmar Stickeler, Eike Simon, Christoph Thomssen, Jens Huober, Carsten Denkert, Joachim Alfer, Christian Jackisch, Valentina Nekljudova, Nicole Burchardi, Sibylle Loibl and for the German Breast Group Investigators

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29506

      The results of the ICE II (Investigational Chemotherapy for Elderly patients trial II) trial demonstrated that nonfrail elderly patients with moderate or high-risk breast cancer can be treated with taxane-based polychemotherapy. However, compound-specific toxicities appear to lower relative dose intensity and therefore potential survival benefits.

  21. Correspondence

  22. Original Articles

    1. Discipline

      Epidemiology
      Folate-mediated one-carbon metabolism genes and interactions with nutritional factors on colorectal cancer risk: Women's Health Initiative Observational Study

      Ting-Yuan David Cheng, Karen W. Makar, Marian L. Neuhouser, Joshua W. Miller, Xiaoling Song, Elissa C. Brown, Shirley A. A. Beresford, Yingye Zheng, Elizabeth M. Poole, Rachel L. Galbraith, David J. Duggan, Nina Habermann, Lynn B. Bailey, David R. Maneval, Marie A. Caudill, Adetunji T. Toriola, Ralph Green and Cornelia M. Ulrich

      Article first published online: 24 JUN 2015 | DOI: 10.1002/cncr.29465

      Evidence from genetic variants suggests that one-carbon metabolism is associated with colorectal cancer risk in postmenopausal women. The essential nutrients in the metabolism (ie, folate, vitamin B6, and vitamin B12) continue to emerge as effect modifiers of genetic influences on colorectal cancer risk.

  23. Commentary

    1. Are high drug prices for hematologic malignancies justified? A critical analysis

      Jagpreet Chhatwal, Michael Mathisen and Hagop Kantarjian

      Article first published online: 23 JUN 2015 | DOI: 10.1002/cncr.29512

      Twenty-nine cost-effectiveness analyses of the treatment of hematologic malignancies published from 1996 to 2012 are evaluated. The current costs of the majority of treatments for hematologic cancers are too high to be deemed cost-effective in the United States.

  24. Original Articles

    1. Discipline

      Epidemiology
      Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States

      Susan Hariri, Michelle L. Johnson, Nancy M. Bennett, Heidi M. Bauer, Ina U. Park, Sean Schafer, Linda M. Niccolai, Elizabeth R. Unger, Lauri E. Markowitz and HPV-IMPACT Working Group

      Article first published online: 22 JUN 2015 | DOI: 10.1002/cncr.29266

      Significant declines in high-grade cervical lesions in young women since 2008 are likely due to reduced cervical cancer screening but could also reflect vaccine impact. See also pages 000-000.

  25. Editorial

    1. Trends in cervical intraepithelial neoplasia Grade 2+ after human papillomavirus vaccination: The devil is in the details

      Harinder Brar and Allan Covens

      Article first published online: 22 JUN 2015 | DOI: 10.1002/cncr.29264

      Eight years since the introduction of the adolescent HPV vaccination programs, as the vaccinated cohort enters adulthood, the impact of these vaccination programs is now being assessed through surrogate markers such as the incidence of high-grade cervical dysplasia (cytology/histology) and the incidence of genital warts. Early data from the HPV-IMPACT study shows that although there has been a noticeable drop in CIN2+ incidence rates, the results may be confounded by the recent changes in cervical screening guidelines. This study is significant in that it is the first to report on changes in high-grade histological abnormalities in the postvaccination era. Despite the confounding effect of changing cervical cancer screening guidelines, the findings cannot be completely ignored. With wider acceptance and standardization of cervical cancer screening guidelines and with an increasing number of women entering the vaccinated cohort, the magnitude of vaccine effectiveness should become more obvious. Further studies are needed to assess the changes in high-grade histological abnormalities in the post-vaccine era.

  26. Erratum

    1. You have free access to this content
  27. Original Articles

    1. Disease Site

      Breast Disease
      Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial

      Jiayu Wang, Binghe Xu, Peng Yuan, Fei Ma, Qing Li, Pin Zhang, Ruigang Cai, Ying Fan, Yang Luo and Qiao Li

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29492

      The median progression-free survival and duration of response are longer in patients with advanced breast cancer who receive combined docetaxel and capecitabine chemotherapy compared with those who receive combined vinorelbine and capecitabine. Hand-foot syndrome occurs more frequently in the docetaxel/capecitabine group.

    2. Hematologic Malignancies
      Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival

      Osnat Bairey, Lev Shvidel, Chava Perry, Eldad J. Dann, Rosa Ruchlemer, Tamar Tadmor and Neta Goldschmidt

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29487

      Primary splenic diffuse large B-cell lymphoma generally presents with abdominal pain, high lactose dehydrogenase levels, and a splenic mass. Splenectomy at diagnosis improves progression-free and overall survival for patients with early-stage disease.

  28. Editorial

    1. Radiofrequency ablation in high-risk stage I non–small cell lung cancer

      Jessica S. Donington

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29501

      Dupuy et al demonstrate excellent safety, tolerability, and preservation of pulmonary function in this multi-institutional, prospective evaluation of radiofrequency ablation for medically unresectable non–small cell lung cancer. Unfortunately, the rate of local recurrence is 40% at 2 years, and this decreases some enthusiasm for its use in patients who have a radiation or surgical option.

  29. Original Articles

    1. Discipline

      Clinical Trials
      Radiofrequency ablation of stage IA non–small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial

      Damian E. Dupuy, Hiran C. Fernando, Shauna Hillman, Thomas Ng, Angelina D. Tan, Amita Sharma, William S. Rilling, Kelvin Hong and Joe B. Putnam

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29507

      This highly controlled, National Cancer Institute–funded, multicenter trial shows that radiofrequency ablation can provide safe and effective treatment for patients with medically inoperable early-stage non–small cell lung cancer in a single outpatient session. Thermal ablation should continue to play a role in medically inoperable patients with lung cancer and perhaps in high-risk operable patients currently treated with sublobar resection.

    2. Psychosocial Oncology
      Parenting changes in adults with cancer

      Cynthia W. Moore, Paula K. Rauch, Lee Baer, William F. Pirl and Anna C. Muriel

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29525

      Declines in parenting self-efficacy beliefs after a cancer diagnosis are correlated to aspects of treatment, health-related quality of life, depression and distress, and concerns about the impact of cancer on dependent children. This study highlights the importance of both identifying parenting concerns as a potential mediator between parental cancer and children's heightened risk for psychosocial difficulties and addressing these concerns to alleviate patient distress.

    3. Disease Site

      Head and Neck Disease
      Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer

      Kristina R. Dahlstrom, Guojun Li, Caroline S. Hussey, Jenny T. Vo, Qingyi Wei, Chong Zhao and Erich M. Sturgis

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29538

      Circulating human papillomavirus (HPV) DNA has been detected in patients with carcinoma of the oropharynx. Progression-free survival appears to be better among patients with pretreatment HPV DNA in their tumors and among patients with HPV-positive tumors who are negative for pretreatment serum HPV DNA compared with patients whose tumors are negative for HPV and those whose tumors are positive for HPV who were positive for pretreatment serum HPV DNA, respectively. Circulating HPV DNA does not appear to have clinical usefulness as a marker for disease recurrence in patients with oropharyngeal carcinoma.

  30. Listen to the Patient

    1. Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer

      Yuhree Kim, Megan Winner, Andrew Page, Diana M. Tisnado, Kathryn A. Martinez, Stefan Buettner, Aslam Ejaz, Gaya Spolverato, Sydney E. Morss Dy and Timothy M. Pawlik

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29530

      The objective of the current study was to characterize the prevalence of the expectation that surgical resection of lung or colorectal cancer might be curative. The overwhelming majority of patients undergoing surgery for lung or colorectal cancer believe that the surgery is likely to be curative, even among those patients with advanced stage IV disease. Greater focus on patient-physician engagement, communication, and barriers to discussing goals of care with patients diagnosed with cancer is needed.

  31. Review Articles

    1. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis

      Darrick K. Li and Raymond T. Chung

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29528

      The rise of direct-acting antivirals heralds an incipient revolution in hepatitis C virus treatment with increasing sustained virological response rates and reductions in hepatitis C virus–associated hepatocellular carcinoma. Epidemiologic and genetic studies are identifying a subpopulation of sustained virological response patients who remain at risk for hepatocellular carcinoma development and would benefit from continued screening.

  32. Original Articles

    1. Disease Site

      Hematologic Malignancies
      A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

      Timothy S. Fenske, Namrata M. Shah, Kyung Mann Kim, Sandeep Saha, Chong Zhang, Arielle E. Baim, John P. Farnen, Adedayo A. Onitilo, Jules H. Blank, Harish Ahuja, Tim Wassenaar, Rubina Qamar, Patrick Mansky, Anne M. Traynor, Ryan J. Mattison and Brad S. Kahl

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29502

      The combination of bortezomib and temsirolimus demonstrates activity in patients with previously treated relapsed/ refractory B-cell non-Hodgkin lymphoma. An overall response rate of 31% was seen, including complete remissions in two heavily pre-treated patients with diffuse large B-cell lymphoma.

    2. Discipline

      Quality of Life
      Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials

      Fabio Efficace, Peter Fayers, Andrea Pusic, Yeliz Cemal, Jane Yanagawa, Marc Jacobs, Andrea la Sala, Valentina Cafaro, Katie Whale, Jonathan Rees, Jane Blazeby and for the European Organization for Research and Treatment of Cancer Quality-of-Life Group (Patient-Reported Outcome Measurements Over Time in Oncology Registry)

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29489

      Five hundred fifty-seven randomized controlled trials with a patient-reported outcome endpoint have been conducted across several cancer specialties within a decade. Overall, the quality of reporting is generally poor according to the Consolidated Standards of Reporting Trials patient-reported outcome extension; however, reporting is higher in randomized controlled trials with a patient-reported outcome as a primary endpoint.

  33. Correspondence

    1. Reply to discrepancies in drug approvals: A global dilemma

      Doreen A. Ezeife, Tony H. Truong and Patricia A. Tang

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29482

    2. Discrepancies in drug approvals: A global dilemma

      Michelle K. Wilson, Katherine Karakasis and Amit M. Oza

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29484

  34. Original Articles

    1. Discipline

      Outcomes Research
      Trends in surveillance for resected colorectal cancer, 2001-2009

      E. Carter Paulson, Christine M. Veenstra, Anil Vachani, Christine A. Ciunci and Andrew J. Epstein

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29469

      There continues to be substantial underuse of guideline-recommended surveillance for stage III and high-risk stage II colorectal cancer survivors, whereas many stage I patients receive intensive surveillance despite an absence of supporting evidence. The 2005 inclusion of computed tomography imaging in the surveillance guidelines has had a negligible impact on computed tomography surveillance in colorectal cancer survivors.

  35. Correspondence

  36. Review Articles

    1. You have full text access to this OnlineOpen article
      Ovarian cancer treatment: The end of empiricism?

      Stephanie Lheureux, Katherine Karakasis, Elise C. Kohn and Amit M. Oza

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncr.29481

      The authors discuss the current understanding of the biology of the ovarian cancer, diagnostic and treatment strategies, and high-priority directions for investigation.

  37. Original Articles

    1. Discipline

      Psychosocial Oncology
      Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer

      Lauren Z. Davis, George M. Slavich, Premal H. Thaker, Michael J. Goodheart, David P. Bender, Laila Dahmoush, Donna M. Farley, Kristian E. Markon, Frank J. Penedo, David M. Lubaroff, Steve W. Cole, Anil K. Sood and Susan K. Lutgendorf

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncr.29516

      Psychosocial factors may be related to sympathetic nervous system activation, with implications for tumor progression in patients with ovarian cancer. The results of the current study indicate that eudaimonic well-being is related to lower tumor norepinephrine in patients with ovarian cancer whereas positive affect and psychological distress are not.

    2. Disease Site

      Chest and Lung Disease
      Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

      Jarushka Naidoo, Camelia S. Sima, Katherine Rodriguez, Natalie Busby, Khedoudja Nafa, Marc Ladanyi, Gregory J. Riely, Mark G. Kris, Maria E. Arcila and Helena A. Yu

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncr.29493

      Epidermal growth factor receptor (EGFR) exon 20 insertions are harbored in 2% of metastatic lung adenocarcinomas, and patients with these tumors have similar survival compared to patients whose tumors harbor sensitizing EGFR mutations. The majority of EGFR exon 20 insertion variants impart resistance to EGFR tyrosine kinase inhibitors.

  38. Review Articles

    1. Immunotherapy in acute myeloid leukemia

      Dolores A. Grosso, Rosemary C. Hess and Mark A. Weiss

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncr.29378

      The authors review immunologic strategies that have been used in the treatment of acute myeloid leukemia. Areas addressed include transplantation and nontransplantation immunologic approaches to acute myeloid leukemia treatment as well as newer therapies, such as chimeric antigen receptors and bispecific T-cell engagers.

  39. Original Articles

    1. Disease Site

      Genitourinary Disease
      Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

      M. Dror Michaelson, Rana R. McKay, Lillian Werner, Michael B. Atkins, Eliezer M. Van Allen, Kara M. Olivier, Jiaxi Song, Sabina Signoretti, David F. McDermott and Toni K. Choueiri

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29503

      This study demonstrates that multimodality therapy with gemcitabine and sunitinib is feasible and is associated with objective responses in patients with sarcomatoid or poor-risk renal cell carcinoma. The results of this study are currently being validated in a randomized phase 2 trial of sunitinib with or without gemcitabine for advanced sarcomatoid renal cell carcinoma (NCT01164228).

    2. Discipline

      Outcomes Research
      Disparities in survival by insurance status in patients with Hodgkin lymphoma

      Rahul R. Parikh, Michael L. Grossbard, B. Lee Green, Louis B. Harrison and Joachim Yahalom

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29518

      Unfavorably insured patients with Hodgkin lymphoma appear to have limited access to care. Significant disparities in outcomes have been identified for patients with unfavorable insurance.

    3. Disease Site

      Gastrointestinal Disease
      Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice

      Anne-Sophie Dussol, Marie-Odile Joly, Cecile Vercherat, Julien Forestier, Valérie Hervieu, Jean-Yves Scoazec, Catherine Lombard-Bohas and Thomas Walter

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29517

      This study reports the activity of gemcitabine and oxaliplatin in neuroendocrine tumors. The outcomes are similar to those with alkylating agents, but the O6-methylguanine-DNA methyltransferase status has no influence.

  40. Correspondence

  41. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery

      Claudia Campanella, Francesca Rappa, Carmelo Sciumè, Antonella Marino Gammazza, Rosario Barone, Fabio Bucchieri, Sabrina David, Giuseppe Curcurù, Celeste Caruso Bavisotto, Alessandro Pitruzzella, Girolamo Geraci, Giuseppe Modica, Felicia Farina, Giovanni Zummo, Stefano Fais, Everly Conway de Macario, Alberto J.L. Macario and Francesco Cappello

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29499

      Heat shock protein 60 is a chaperonin involved in tumorigenesis but its participation in tumor development and progression is not well understood and its value as a tumor biomarker has not been fully elucidated. In the current study, the authors present evidence supporting the theory that heat shock protein 60 has potential as biomarker as well as a therapeutic target in patients with colon cancer.

    2. Discipline

      Symptom Control and Palliative Care
      Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study

      David Hui, Omar Shamieh, Carlos Eduardo Paiva, Pedro Emilio Perez-Cruz, Jung Hye Kwon, Mary Ann Muckaden, Minjeong Park, Sriram Yennu, Jung Hun Kang and Eduardo Bruera

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29437

      When a symptom response is being assessed, how much of a change on a 0- to 10-point numeric rating scale is considered clinically significant? In this multicenter, prospective, longitudinal study involving 796 patients with advanced cancer, the minimal clinically important difference is universally a 1-point difference for both improvement and deterioration for each of the 10 symptoms in the Edmonton Symptom Assessment Scale, one of the most widely used symptom assessment batteries in oncology.

    3. Variation in symptom distress in underserved Chinese American cancer patients

      Lara K. Dhingra, Kin Lam, William Cheung, Theresa Shao, Zujun Li, Sandra Van de Maele, Victor T. Chang, Jack Chen, Huiyan Ye, Rhoda Wong, Wan Ling Lam, Selina Chan, Marilyn Bookbinder, Nathan F. Dieckmann and Russell Portenoy

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29497

      In a large sample of community-dwelling Chinese American cancer patients, symptom prevalence has been found to be high, and clinically relevant subgroups with different profiles of symptom distress can be identified. These data may inform patient management and improve disparities in care.

    4. Medical Oncology
      Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues

      Bertrand Brieau, Laetitia Dahan, Yann De Rycke, Tarek Boussaha, Philippe Vasseur, David Tougeron, Thierry Lecomte, Romain Coriat, Jean-Baptiste Bachet, Pierre Claudez, Aziz Zaanan, Pauline Soibinet, Jérome Desrame, Anne Thirot-Bidault, Isabelle Trouilloud, Florence Mary, Lysiane Marthey, Julien Taieb, Wulfran Cacheux and Astrid Lièvre

      Article first published online: 5 JUN 2015 | DOI: 10.1002/cncr.29471

      Second-line chemotherapy for advanced biliary tract cancer may provide disease control in select patients, but the prognosis remains poor, and no particular regimen seems superior to others. Good performance status and disease control by the first-line treatment are both associated with longer survival.

    5. Radiation Oncology
      What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?

      John A. Vargo, Beant S. Gill, Goundappa K. Balasubramani and Sushil Beriwal

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29491

      In what to the authors' knowledge is the largest outcomes analysis for early-stage low-grade follicular lymphoma with over 35,000 patients spanning a 14-year period from 1998 through 2012, radiotherapy use continues to decline in favor of alternative treatment strategies, most notably observation without initial treatment and single-agent chemotherapy. This concerning decline is coupled with findings of improved overall survival in patients receiving radiotherapy, either alone or in conjunction with systemic therapy, even after adjusting for indication bias.

  42. Erratum

    1. You have free access to this content
  43. Original Articles

    1. Discipline

      Psychosocial Oncology
      The lasting impact of the therapeutic alliance: Patient-oncologist alliance as a predictor of caregiver bereavement adjustment

      Kelly M. Trevino, Paul K. Maciejewski, Andrew S. Epstein and Holly G. Prigerson

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29505

      Cancer patients’ perceptions of a strong therapeutic alliance with their oncologist predict better caregiver mental health 6 months after the patient's death based on caregivers’ self-report and interviewers’ postloss rating. By developing a strong relationship with the patient, the oncologist may benefit the caregiver in addition to the patient.

  44. Review Articles

    1. The mu opioid receptor: A new target for cancer therapy?

      Patrick A. Singleton, Jonathan Moss, Daniel D. Karp, Johnique T. Atkins and Filip Janku

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29460

      In this review, the authors present preclinical and clinical data that support their hypothesis that the mu opioid receptor is a potential target for cancer therapy because of its plausible role in tumor progression. The authors also propose the hypothesis that peripheral opioid antagonists such as methylnaltrexone, which reverses the peripheral effects of mu opioids but maintains centrally mediated analgesia and is approved by the US Food and Drug Administration to treat opioid-induced constipation, can be used to target the mu opioid receptor.

  45. Editorial

    1. Coordination of care in colon cancer

      George J. Chang and Scott Kopetz

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29473

      Solutions to the problem of a “system in crisis” for cancer care delivery should be of the highest priority for academics, policymakers, providers, patient advocacy organizations, and funding agencies alike. Although programs such as the Affordable Care Act emphasize the principles of coordinated and patient-centered care to improve outcomes and value, real-world examples such as the current study help to shed light on how the principles may be implemented to improve the delivery of cancer care.

  46. Original Articles

    1. Discipline

      Outcomes Research
      Fragmentation in specialist care and stage III colon cancer

      Tanvir Hussain, Hsien-Yen Chang, Christine M. Veenstra and Craig Evan Pollack

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29474

      A significant proportion of colon cancer patients receive surgical and medical oncology care fragmented across more than 1 hospital. This fragmentation increases costs but may not affect survival.

    2. Disease Site

      Hematologic Malignancies
      Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes

      Zoe K. McQuilten, Vijaya Sundararajan, Nick Andrianopoulos, David J. Curtis, Erica M. Wood, Lynda J. Campbell and Meaghan Wall

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29396

      A monosomal karyotype is an independent predictor of a poor prognosis for patients with myelodysplastic syndromes. The prognostic utility of a monosomal karyotype is independent of a complex karyotype.

    3. Discipline

      Radiation Oncology
      Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival

      Alexandra D. Jensen, Anna V. Nikoghosyan, Melanie Poulakis, Angelika Höss, Thomas Haberer, Oliver Jäkel, Marc W Münter, Daniela Schulz-Ertner, Peter E. Huber and Jürgen Debus

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29443

      Patients with adenoid cystic carcinoma (ACC) of the head and neck who receive intensity-modulated radiotherapy plus carbon ion boost (C12 therapy) at a biologically effective dose of 80 Gray using modern photon techniques achieve superior locoregional control and overall survival rates compared with those who those who receive modern photon radiotherapy; and, among those who do receive C12, no statistical difference is observed between inoperable and partially resected tumors. Thus, definitive radiotherapy is identified as a valid treatment alternative, and extensive and morbid resections in patients with advanced ACC may need to be reconsidered.

    4. Disparities Research
      Elimination of cost-sharing and receipt of screening for colorectal and breast cancer

      Stacey A. Fedewa, Michael Goodman, W. Dana Flanders, Xuesong Han, Robert A. Smith, Elizabeth M. Ward, Chyke A. Doubeni, Ann Goding Sauer and Ahmedin Jemal

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29494

      Overall, adjusted colorectal screening prevalence increased between 2008 and 2013 for low-income, least-educated, and Medicare-insured respondents but not in high-income, most-educated, and privately insured respondents. The increase in colorectal cancer screening prevalence between 2008 and 2013 among respondents with low socioeconomic status may in part reflect the removal of cost-sharing through the Patient Protection and Affordable Care Act.

    5. Disease Site

      Skin
      Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma

      Franz O. Smith, Binglin Yue, Suroosh S. Marzban, Brooke L. Walls, Michael Carr, Ryan S. Jackson, Christopher A. Puleo, Tapan Padhya, C. Wayne Cruse, Ricardo J. Gonzalez, Amod A. Sarnaik, Michael J. Schell, Ronald C. DeConti, Jane L. Messina, Vernon K. Sondak and Jonathan S. Zager

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29452

      In Merkel cell carcinoma, increasing primary tumor diameter and increasing tumor depth are independently predictive of a positive sentinel lymph node and disease-specific survival. Tumor depth should be routinely reported when primary Merkel cell carcinoma specimens are being evaluated histopathologically.

    6. Discipline

      Clinical Trials
      Estrogen and colorectal cancer incidence and mortality

      Sayeh Lavasani, Rowan T. Chlebowski, Ross L. Prentice, Ikuko Kato, Jean Wactawski-Wende, Karen C. Johnson, Alicia Young, Rebecca Rodabough, F. Allan Hubbell, Ali Mahinbakht and Michael S. Simon

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29464

      According to the Women's Health Initiative randomized controlled clinical trial, estrogen use in postmenopausal women with prior hysterectomy does not influence the incidence of colorectal cancer or colorectal cancer deaths.

    7. Epidemiology
      You have full text access to this OnlineOpen article
      Universal tumor screening for lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers

      Jessica Ezzell Hunter, Jamilyn M. Zepp, Mari J. Gilmore, James V. Davis, Elizabeth J. Esterberg, Kristin R. Muessig, Susan K. Peterson, Sapna Syngal, Louise S. Acheson, Georgia L. Wiesner, Jacob A. Reiss and Katrina A.B. Goddard

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29470

      In the current study, perspectives among patients newly diagnosed with colorectal cancer are assessed regarding universal tumor screening for Lynch syndrome. The majority of patients appear to have a positive attitude toward screening and endorse the benefits for themselves and their families, whereas potential barriers include concerns over the cost of additional genetic counseling and testing.

    8. Quality of Life
      Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma?

      Denise J. Spector, Devon Noonan, Deborah K. Mayer, Habtamu Benecha, Sheryl Zimmerman and Sophia K. Smith

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29490

      Healthy lifestyle behaviors appear to be related to better health-related quality of life, both mentally and physically, in long-term survivors of non-Hodgkin lymphoma. The majority of these individuals are not meeting American Cancer Society guidelines for health behaviors, which could impact their overall well-being and longevity.

  47. Editorial

    1. Prognostic factors and immunobiologic insights into Merkel cell carcinoma

      Dale Han and Jayasri G. Iyer

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29453

      Merkel cell carcinoma is an aggressive cutaneous neuroendocrine cancer, and although the current staging system takes into account several prognostic features, further study is needed to better determine whether other clinicopathologic features are also predictive of survival. The discovery of the Merkel cell polyomavirus with persistently expressed viral epitopes and an understanding of the various immune evasion mechanisms in Merkel cell carcinoma tumors provide an exciting and unique opportunity for the development of rational immune therapies to improve patient outcomes for this biologically unique, virus-associated cancer.

  48. Original Articles

    1. Discipline

      Radiation Oncology
      Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer

      Lora S. Wang, Colin T. Murphy, Karen Ruth, Nicholas G. Zaorsky, Marc C. Smaldone, Mark L. Sobczak, Alexander Kutikov, Rosalia Viterbo and Eric M. Horwitz

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29472

      Obesity is an epidemic affecting greater than one-third of adults in the United States, and its incidence has more than doubled in the last 40 years. In the cohort of patients with prostate cancer in the current study, increasing body mass index appears to be associated with an increased risk of biochemical failure, distant metastases, and prostate cancer-specific and overall mortality in patients treated with dose-escalated intensity-modulated radiotherapy and daily image guidance.

    2. Disease Site

      Hepatobiliary Disease
      Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma

      Hui Wang, Ying Liu, Xiu Wang, Donghui Liu, Zhiqiang Sun, Chun Wang, Gang Jin, Beiguang Zhang and Shilong Yu

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29456

      The therapeutic potential of arsenic trioxide for the treatment of cancer has been accumulatively addressed. However, few randomized controlled studies have been conducted for the treatment of hepatocellular carcinoma with arsenic trioxide. In this article, a randomized controlled study is presented, and the efficacy and safety of adjuvant arsenic trioxide treatment in hepatocellular carcinoma patients receiving locoregional therapy are determined. The findings may provide valuable insights into the clinical use of adjuvant arsenic trioxide therapy for patients with hepatocellular carcinoma.

    3. Hematologic Malignancies
      Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia

      Christine M. Gronseth, Scott E. McElhone, Barry E. Storer, Kathleen A. Kroeger, Vicky Sandhu, Matthew L. Fero, Frederick R. Appelbaum, Elihu H. Estey and Min Fang

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29475

      Copy-neutral loss of heterozygosity is an independent prognostic factor for early disease recurrence in patients with acute myeloid leukemia. Genomic complexity revealed by chromosome genomic array testing conveys the same poor prognosis in these patients as did complex cytogenetics.

    4. Discipline

      Outcomes Research
      You have full text access to this OnlineOpen article
      Impact of aggressive management and palliative care on cancer costs in the final month of life

      Matthew C. Cheung, Craig C. Earle, Jagadish Rangrej, Thi H. Ho, Ning Liu, Lisa Barbera, Refik Saskin, Joan Porter, Soo Jin Seung and Nicole Mittmann

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29485

      Cancer patients who receive aggressive end-of-life care incur 43% higher costs than those managed nonaggressively; these costs are driven by a heavy dependence on acute institutional care. Palliative consultation may partially offset these costs by tempering the tendency toward aggressive management and offer resultant savings.

    5. Medical Oncology
      Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

      Karen L. Reckamp, Marianna Koczywas, Mihaela C. Cristea, Jonathan E. Dowell, He-Jing Wang, Brian K. Gardner, Ginger L. Milne, Robert A. Figlin, Michael C. Fishbein, Robert M. Elashoff and Steven M. Dubinett

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29480

      This randomized trial evaluates the efficacy of combined erlotinib and celecoxib in patients with advanced non-small cell lung cancer and builds on previous work that defined urinary prostaglandin E metabolite as a marker for activation of the cyclooxygenase 2 pathway, demonstrating an improvement in progression-free survival among those patients with elevated baseline levels. A benefit for patients with wild-type epidermal growth factor receptor (EGFR), a population that has limited benefit with EGFR tyrosine kinase inhibitor therapy, also is identified.

  49. Editorial

    1. Cyclooxygenase 2 inhibition in patients with non-small cell lung cancer: Is this still a valid target for therapy?

      Shirish M. Gadgeel

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29479

      In a randomized trial, the combination of the cyclooxygenase 2 (COX-2) inhibitor celecoxib with erlotinib demonstrated improved progression-free survival in patients with elevated baseline urinary prostaglandin E metabolite levels. Further studies are required to assess the usefulness of this biomarker to identify those patients with non-small cell lung cancer who are likely to benefit from COX-2 inhibitors.

VIEW

  1. 1 - 100
  2. 101 - 147

SEARCH

SEARCH BY CITATION